Wanbury Limited (IN:WANBURY)
:WANBURY
WANBURY Stock Chart & Stats
₹235.40
-₹13.70(-4.99%)
At close: 4:00 PM EST
₹235.40
-₹13.70(-4.99%)
Day’s Range― - ―
52-Week Range₹162.00 - ₹330.00
Previous CloseN/A
Volume54.35K
Average Volume (3M)8.26K
Market Cap
₹8.40B
Enterprise Value₹10.48B
Total Cash (Recent Filing)₹131.55M
Total Debt (Recent Filing)₹1.96B
Price to Earnings (P/E)12.5
Beta1.99
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.50
Shares Outstanding34,939,400
10 Day Avg. Volume8,584
30 Day Avg. Volume8,255
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)14.81
Price to Sales (P/S)1.46
P/FCF Ratio-38.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthA ~16% revenue growth rate indicates the company is regaining top-line momentum across products and markets. Over 2-6 months this supports scale benefits, better utilization of manufacturing capacity and underpins reinvestment in product lines and export expansion.
Improving Operating MarginsImproved gross, EBIT and EBITDA margins reflect better cost control and pricing mix, enhancing durable profitability. Sustained margin expansion increases cash generation potential per revenue dollar and strengthens competitiveness against peers in generics/APIs.
Restored Shareholders' EquityTransition from negative to positive equity signals a meaningful balance-sheet repair, reducing default risk and improving access to capital. This provides a structural buffer for investment, regulatory compliance and multi-market operations over coming quarters.
Bears Say
High LeverageElevated leverage increases interest burden and limits strategic flexibility. Over several months higher debt servicing needs can strain cash flow, constrain capex or M&A options, and heighten vulnerability to input-cost or demand shocks in pharma markets.
Negative Free Cash FlowPersistent negative free cash flow despite better operating cash suggests capital or working-capital demands outpacing earnings. This structurally limits self-funded growth, may force external financing, and raises risk during regulatory or tender-driven revenue cycles.
Profitability VolatilityFluctuating net margins reduce earnings visibility and complicate long-term planning. For a pharma firm relying on contracts and regulated markets, inconsistent margins can hinder sustained R&D, marketing investments and weaken long-run ability to smooth earnings through product cycles.
Wanbury Limited News
WANBURY FAQ
What was Wanbury Limited’s price range in the past 12 months?
Wanbury Limited lowest stock price was ₹162.00 and its highest was ₹330.00 in the past 12 months.
What is Wanbury Limited’s market cap?
Wanbury Limited’s market cap is ₹8.40B.
When is Wanbury Limited’s upcoming earnings report date?
Wanbury Limited’s upcoming earnings report date is May 14, 2026 which is in 33 days.
How were Wanbury Limited’s earnings last quarter?
Wanbury Limited released its earnings results on Feb 05, 2026. The company reported ₹4.5 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.5.
Is Wanbury Limited overvalued?
According to Wall Street analysts Wanbury Limited’s price is currently Overvalued.
Does Wanbury Limited pay dividends?
Wanbury Limited pays a Notavailable dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Wanbury Limited dividends here
What is Wanbury Limited’s EPS estimate?
Wanbury Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wanbury Limited have?
Wanbury Limited has 34,939,400 shares outstanding.
What happened to Wanbury Limited’s price movement after its last earnings report?
Wanbury Limited reported an EPS of ₹4.5 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.532%.
Which hedge fund is a major shareholder of Wanbury Limited?
Currently, no hedge funds are holding shares in IN:WANBURY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. Wanbury Limited also exports its products. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Technical Analysis
Kilitch Drugs (India) Limited
―
Kopran Limited
―
Lincoln Pharmaceuticals Ltd
―
Sakar Healthcare Ltd
―
Themis Medicare Limited
―